13.25
1.84%
+0.24
After Hours:
13.30
0.05
+0.38%
Overview
News
Price History
Option Chain
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva- Pharmaceutical Industries Ltd. ADR stock is currently priced at $13.25, with a 24-hour trading volume of 8.47M.
It has seen a +1.84% increased in the last 24 hours and a -5.76% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $12.99 pivot point. If it approaches the $13.34 resistance level, significant changes may occur.
Previous Close:
$13.01
Open:
$12.805
24h Volume:
8.47M
Market Cap:
$15.01B
Revenue:
$15.85B
Net Income/Loss:
$-559.00M
P/E Ratio:
-6.625
EPS:
-2
Net Cash Flow:
$842.00M
1W Performance:
+3.68%
1M Performance:
-5.76%
6M Performance:
+61.39%
1Y Performance:
+61.00%
Teva- Pharmaceutical Industries Ltd. ADR Stock (TEVA) Company Profile
Name
Teva- Pharmaceutical Industries Ltd. ADR
Sector
Phone
972 3 914 8171
Address
5 Basel Street, Petach Tikva
Teva- Pharmaceutical Industries Ltd. ADR Stock (TEVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Nov-27-23 | Upgrade | UBS | Neutral → Buy |
Jul-06-23 | Upgrade | UBS | Sell → Neutral |
May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-04-22 | Downgrade | UBS | Neutral → Sell |
Oct-21-22 | Resumed | Jefferies | Buy |
Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jun-14-22 | Resumed | UBS | Neutral |
May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jan-27-22 | Downgrade | Argus | Buy → Hold |
Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-04-21 | Downgrade | UBS | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-25-20 | Initiated | Oppenheimer | Perform |
Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-27-20 | Resumed | Goldman | Neutral |
Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
Apr-24-20 | Resumed | Citigroup | Neutral |
Apr-06-20 | Upgrade | UBS | Neutral → Buy |
Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-10-19 | Resumed | Credit Suisse | Neutral |
Jul-05-19 | Upgrade | Argus | Hold → Buy |
Jun-11-19 | Initiated | Barclays | Underweight |
Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
May-28-19 | Downgrade | UBS | Buy → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Mar-07-19 | Resumed | UBS | Buy |
View All
Teva- Pharmaceutical Industries Ltd. ADR Stock (TEVA) Latest News
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks Investment Research
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
The Motley Fool
3 No-Brainer Stocks to Buy With $600 Right Now
The Motley Fool
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Zacks Investment Research
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Zacks Investment Research
Teva- Pharmaceutical Industries Ltd. ADR Stock (TEVA) Financials Data
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Revenue 2024
TEVA reported a revenue (TTM) of $15.85 billion for the quarter ending December 31, 2023, a +6.18% rise year-over-year.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Net Income 2024
TEVA net income (TTM) was -$559.00 million for the quarter ending December 31, 2023, a +77.14% increase year-over-year.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Cash Flow 2024
TEVA recorded a free cash flow (TTM) of $842.00 million for the quarter ending December 31, 2023, a -19.19% decrease year-over-year.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Earnings per Share 2024
TEVA earnings per share (TTM) was -$0.47 for the quarter ending December 31, 2023, a +77.83% growth year-over-year.
Teva- Pharmaceutical Industries Ltd. ADR Stock (TEVA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kalif Eliyahu Sharon | EVP, Chief Financial Officer |
Mar 06 '24 |
Sale |
13.52 |
77,550 |
1,048,119 |
203,691 |
Sabag Mark | EVP, International Markets |
Mar 05 '24 |
Sale |
13.52 |
100,000 |
1,352,090 |
382,590 |
Daniell Richard | Exec. VP, European Commercial |
Mar 05 '24 |
Sale |
13.52 |
48,629 |
657,240 |
69,770 |
Conway Vikki L | See "Remarks" |
Mar 05 '24 |
Sale |
13.52 |
1,427 |
19,286 |
15,219 |
Daniell Richard | Exec. VP, European Commercial |
Mar 04 '24 |
Sale |
13.34 |
95,762 |
1,277,207 |
69,770 |
Francis Richard D | President and CEO |
Mar 04 '24 |
Sale |
13.34 |
31,061 |
414,270 |
123,295 |
Hughes Eric A | See "Remarks" |
Mar 04 '24 |
Sale |
13.34 |
8,045 |
107,299 |
16,855 |
Conway Vikki L | See "Remarks" |
Mar 04 '24 |
Sale |
13.37 |
3,532 |
47,234 |
6,617 |
Daniell Richard | Exec. VP, European Commercial |
Feb 28 '24 |
Sale |
13.12 |
20,599 |
270,176 |
69,770 |
Drape Eric | Executive VP Global Operations |
Feb 28 '24 |
Sale |
13.12 |
9,815 |
128,734 |
9,701 |
About Teva- Pharmaceutical Industries Ltd. ADR
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Cap:
|
Volume (24h):